HK Stock Market Move | FOURSEMI (03625) surged nearly 10% during the trading session as the group actively promotes diversification in audio products, leading to a significant increase in revenue from in-car audio products.
Fourier (03625) rose nearly 10% intraday, and as of the time of writing, it is up 7.61%, priced at HKD 96.9, with a trading volume of HKD 4.6585 million.
FOURSEMI (03625) saw an intraday increase of nearly 10%; as of the time of writing, it has risen by 7.61%, reaching HKD 96.9, with a transaction volume of HKD 4.6585 million.
In terms of news, FOURSEMI announced that in the first half of the year, the group actively promoted the diversified application layout of audio products, building a more balanced audio business portfolio with stronger risk resistance. Notably, the revenue from in-vehicle audio products saw a year-on-year growth rate of over 30,000%, expanding to several leading new energy vehicle manufacturers in the industry; the revenue from tactile feedback chip products grew by over 330% year-on-year, achieving large-scale shipments in the fields of smartwatches and smart glasses, and adapting to scenarios such as the Siasun Robot & Automation dexterous hand and gaming consoles/controllers, meeting the operational demands for intelligent and refined AI terminals.
Public information shows that FOURSEMI Semiconductor is a leading domestic sensing intelligent chip design company, operating under a Fabless light asset model, focusing on the research, design, and sales of smart audio and tactile feedback chips. Its core highlights stand out, making it a benchmark enterprise in the domestic substitution track. Based on the projected shipping volume in 2024, the company ranks among the top three in the global amplifier audio chip sector, with a second place in the Chinese market, and holding the first domestic market share for audio chips dedicated to smart screens, solidifying its leading position in the industry.
Related Articles

CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.

RECOMMEND





